Can Dayvigo Cause Ectopic Atrial Rhythm?
No, Dayvigo (lemborexant) does not cause ectopic atrial rhythm (EAR) based on available evidence. The FDA drug label does not list ectopic atrial rhythm as a known adverse effect, and comprehensive cardiac safety studies specifically evaluating lemborexant's effects on cardiac rhythm have not identified this arrhythmia 1, 2.
Cardiac Safety Profile of Lemborexant
Lemborexant has been extensively evaluated for cardiac effects, particularly QT prolongation, and has demonstrated a favorable cardiac safety profile. A concentration-response modeling study using high-precision ECG measurements from multiple ascending-dose trials found no clinically significant QT prolongation even at plasma concentrations 8-fold higher than therapeutic levels 2. The model-predicted QTc effect at the highest observed concentration (400 ng/mL) was only 1.1 milliseconds (90% CI: -3.49 to 5.78 milliseconds), well below the threshold of clinical concern 2.
Known Cardiac Effects
The FDA-approved drug label for Dayvigo does not mention any arrhythmogenic effects, including ectopic atrial rhythm 1. The primary adverse effects are:
- Somnolence (most common side effect)
- Sleep paralysis
- Temporary leg weakness
- Complex sleep behaviors
- Increased fall risk, particularly in elderly patients
Context: Ectopic Atrial Rhythm vs. Drug-Induced Arrhythmias
Ectopic atrial rhythm is defined as atrial depolarization from a pacemaker other than the sinus node with a rate <50 bpm 3, 4. This is distinct from atrial fibrillation or other tachyarrhythmias. While drug-induced atrial fibrillation (DIAF) is a recognized phenomenon with certain medications—particularly anticancer drugs, cardiovascular agents, and some antiarrhythmics 5—lemborexant does not appear in the literature as a causative agent for any atrial arrhythmias.
Clinical Considerations
In a 37-year-old patient with a previously normal ECG, if ectopic atrial rhythm develops after starting lemborexant, alternative etiologies should be investigated:
- Vagal tone changes during sleep (physiologic)
- Underlying cardiac conditions not previously detected
- Electrolyte abnormalities
- Concomitant medications (lemborexant has CYP3A interactions) 6
- Other medical conditions (thyroid dysfunction, structural heart disease)
The temporal association with lemborexant initiation would likely be coincidental rather than causal, given the absence of any mechanistic or clinical evidence linking this medication to ectopic atrial rhythm.
Drug Interactions and Cardiac Monitoring
While lemborexant itself does not cause arrhythmias, clinicians should be aware that it is metabolized by CYP3A enzymes. Concomitant use with strong CYP3A inhibitors increases lemborexant exposure 3.7- to 4-fold 6, though even at these elevated levels, cardiac rhythm disturbances have not been reported.
If ectopic atrial rhythm is documented in a patient taking lemborexant, standard cardiac evaluation should proceed as it would for any patient with this finding, including assessment for structural heart disease, electrolyte abnormalities, and other potential causes 3, 7. Discontinuation of lemborexant is not indicated based solely on the presence of ectopic atrial rhythm, as there is no established causal relationship.